EP3177365A4 - Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists - Google Patents

Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists Download PDF

Info

Publication number
EP3177365A4
EP3177365A4 EP15830204.2A EP15830204A EP3177365A4 EP 3177365 A4 EP3177365 A4 EP 3177365A4 EP 15830204 A EP15830204 A EP 15830204A EP 3177365 A4 EP3177365 A4 EP 3177365A4
Authority
EP
European Patent Office
Prior art keywords
agonists
identifying
receptor pathway
ahr receptor
sebosuppressive activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15830204.2A
Other languages
German (de)
French (fr)
Other versions
EP3177365A1 (en
Inventor
Jean Hilaire Saurat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THESAN PHARMACEUTICALS Inc
Original Assignee
THESAN PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THESAN PHARMACEUTICALS Inc filed Critical THESAN PHARMACEUTICALS Inc
Publication of EP3177365A1 publication Critical patent/EP3177365A1/en
Publication of EP3177365A4 publication Critical patent/EP3177365A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP15830204.2A 2014-08-06 2015-08-05 Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists Withdrawn EP3177365A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034005P 2014-08-06 2014-08-06
US201462041751P 2014-08-26 2014-08-26
PCT/US2015/043833 WO2016022703A1 (en) 2014-08-06 2015-08-05 Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists

Publications (2)

Publication Number Publication Date
EP3177365A1 EP3177365A1 (en) 2017-06-14
EP3177365A4 true EP3177365A4 (en) 2018-01-10

Family

ID=55264515

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15830204.2A Withdrawn EP3177365A4 (en) 2014-08-06 2015-08-05 Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists

Country Status (2)

Country Link
EP (1) EP3177365A4 (en)
WO (1) WO2016022703A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093207A1 (en) * 2008-01-23 2009-07-30 Jean Hilaire Saurat Composition for topical use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU84491A1 (en) * 1982-11-26 1984-06-13 Oreal ANTI-ACNE COMPOSITION CONTAINING AS AN ACTIVE COMPOUND A DERIVATIVE OF ISOTHIAZOLO- (5,4B) PYRIDINE ONE-3
US6008254A (en) * 1997-05-09 1999-12-28 Kligman; Douglas E. Method of treating skin disorders with high-strength tretinoin
JP4889093B2 (en) * 2002-07-01 2012-02-29 マリア ビラーニ， Sponge-based therapeutic compositions for the treatment and prevention of skin diseases
TW201311295A (en) * 2011-06-03 2013-03-16 Allergan Inc Targeted delivery of retinoid compounds to the sebaceous glands
EP2664919A1 (en) * 2012-05-15 2013-11-20 Jean Hilaire Saurat A method for identifying the AhR receptor ligands having a therapeutic sebosuppressive activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093207A1 (en) * 2008-01-23 2009-07-30 Jean Hilaire Saurat Composition for topical use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRIMALT R ET AL: "Premature familial sebaceous hyperplasia: Successful response to oral isotretinoin in three patients", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, MOSBY, INC, US, vol. 37, no. 6, 1 December 1997 (1997-12-01), pages 996 - 998, XP027420679, ISSN: 0190-9622, [retrieved on 19971201], DOI: 10.1016/S0190-9622(97)70082-3 *
See also references of WO2016022703A1 *

Also Published As

Publication number Publication date
WO2016022703A1 (en) 2016-02-11
EP3177365A1 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
EP3149689A4 (en) System and method for controlled knowledge system management
EP3193600A4 (en) Smyd inhibitors
EP3188787A4 (en) Methods and devices for transcarotid access
EP3178265A4 (en) Systems and methods for dual-connectivity operation
EP3154989A4 (en) Beta-lactamase inhibitors
EP3160396A4 (en) Systems and methods for anchoring an implant
EP3141051A4 (en) Systems and methods for dual-connectivity operation
EP3100557A4 (en) Systems and methods for dual-connectivity operation
EP3100578A4 (en) Systems and methods for dual-connectivity operation
GB201421083D0 (en) Enzyme inhibitors
EP3116878A4 (en) Fxr agonists and methods for making and using
EP3116503A4 (en) Hptp-beta inhibitors
GB201421088D0 (en) New enzyme inhibitors
EP3340683A4 (en) Method and device for anchor replacement
EP3193902A4 (en) mTORC1 INHIBITORS
EP3274704A4 (en) Method and system for examining eggs
GB201421085D0 (en) New enzyme inhibitors
EP3217867A4 (en) Systems and methods for performing electrocardiograms
EP3241165A4 (en) Systems and methods for inferred review
EP3253408A4 (en) Anti-pre-bcr antagonists and methods
EP3332215A4 (en) Systems and methods for northfinding
EP3106077A4 (en) Manipulator and manipulator system
EP3148971A4 (en) Deubiquitinase inhibitors
EP3151743A4 (en) Systems and methods for detecting ecg subwaveforms
EP3154889A4 (en) Method for using an elevator system and elevator system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170301

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20171207

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 17/08 20060101AFI20171201BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180714